Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
--------
Question: Paragraph: "The story includes the cost of this test $1,625 and mentions that insurance companies currently don’t cover the cost of the new genetic test for breast cancer. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. It is not clear how this test improves on these current practice as there was no evidence presented about it. The story appropriately expresses caution when presenting the value of this new test to predict a woman’s lifetime risk of developing cancer. There is a wide range of experts interviewed, all of whom express concern about the current available evidence for the predictive value of this test. Most experts advise against women taking this test, and the American Cancer Society does not promote the test. The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening. Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy). The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. Additionally, peer-reviewed studies need to be done to determine the best course of prevention if a woman chooses to take the test and discovers she is at higher risk of developing breast cancer. Because the story raised appropriate questions about the quality of the evidence, we give this a satisfactory score. The story lists the annual incidence of new breast cancers and mortality rate. The story is tempered in reporting about a new genetic test which may or may not be another option for women looking to assess their risk. The story mentions that knowing individual risk may inform a woman’s decision whether to increase surveillance and/or take chemoprevention medication, such as tamoxifen. Several leading breast cancer researchers, a member of the American Cancer Society and a spokesperson for the FDA are interviewed for this story. These interviewees do not have a vested interest in this test–unlike Decode’s chief executive, who is also interviewed, mainly promoting his company’s product. Researchers help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts. The story mentions current prevention guidelines for women who are considered at higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However, the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer  mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. The test discussed in this story has not been studied long enough, nor have results of company studies been subjected to an external review. The focus of the story is a new, widely available genetic test. The story says that any doctor can order this test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there are questions about the validity of tests that have not been subjected to external review. The story notes that there are other genetic tests, but this is one of the first for breast cancer for women who do not carry the BRCA1/2 gene. The story does not mention that there are several other risk calculators to estimate a women’s risk. The story does not rely on the Decode Genetics press release. There is independent reporting and a balanced review of this new genetic test." Claim: Firm says test judges risk for common breast cancers

Answer: "The focus of the story is a newly available genetic test to assess a woman’s risk of developing of developing one of the more common forms of breast cancer. The story does not provide any evidence about the test itself (despite alluding to it). The story does mention that this test has not been validated in an external review, so any evidence would be from company-sponsored studies. The story notes that the FDA does not regulate this or similar types of predictive genetic tests, and there is concern about the validity of such tests that have not been subjected to external review. The test manufacturer CEO’s speculation that insurance companies will eventually cover the test because it’s easy to perform and ""any doctor can order the test"" is an inappropriate rationale for any screening, especially when such screening may place a woman at risk for unnecessary surgery or other treatments. The story mentions current prevention guidelines for women who are considered higher than average risk of developing breast cancer. This includes additional surveillance with MRI and mammography, chemoprevention and adopting a healthier lifestyle, namely reducing alcohol consumption and lowering body fat. However,the evidence of survival benefit for lifestyle and screening is fairly limited. Most of recent decrease in breast cancer mortality is attributed to advances in treatment not necessarily screening. Currently, breast cancer risk for women who do not carry the BRAC1/2 genes is determined via population-based calculators such as the Gail Risk Model. This tool provides an estimated 5-year risk and is only validated for Caucasian women, so a well-validated, individualized predictive test would, in theory, be useful for some women. It is not clear how the new genetic test improves on this current practice, as there was no evidence presented. Researchers and clinicians interviewed help educate the reader about a new test may have many more cons than pros. The story does note, via a patient advocate, that some women may still go ahead with the test if they feel it may help guide them in future breast cancer prevention efforts."


Question: Paragraph: We’ll give this story a Satisfactory rating in this category since it does mention the $1,000 cost of a colonoscopy and that one of the two at-home screening tests costs about $25. But readers would benefit more by knowing the average costs of the two alternatives, rather than just the cost of one. This story focuses on the available methods of colorectal screening, comparing them based on available data, and points out that the two at-home screening kits are comparably effective to the two invasive procedures: sigmoidoscopy and colonoscopy. One of the at-home tests — the FIT, or fecal immunochemical test — when used, is estimated to prevent 20-23 deaths per thousand people screened, while estimates among those using colonoscopy suggest 22-24 deaths are prevented per thousand people screened. The story is clear in saying that there has been no head-to-head comparative study pitting the techniques against each other. The story gets a Satisfactory rating here since it does mention that with colonoscopy, there’s “a small but real risk of harm, such as a perforation” from the screening test. But, as with all screening methods, there is the possibility of false positives or false negatives with the at-home tests which could produce either false confidence or needless worry, not insignificant issues. We would have liked the story even better had it mentioned these factors. The story is quite open with the fact that comparative data assessing the various screening methods against each other are not available, but it strengthens its offerings by citing recommendations from both the US Preventive Services Task Force and the Canadian Task Force on Preventive Health Care. The recommendations of these independent groups are based on a rigorous evaluation of the highest-quality evidence available. Colon cancer is the second-leading form of cancer-related death in the country; the story does not disease monger. The story quotes three independent sources for information and the recommendations of agencies from two different governments. There is no suggestion that in a story offering a selection of screening techniques, with no one preferred above another, that there is any issue with conflicts of interest. Since this story is totally about the available alternatives for colorectal cancer screening, it easily gets a Satisfactory rating. Both colonoscopy and sigmoidoscopy have been available for years and the at-home screening tests mentioned in the story are said to be available through a patient’s doctor’s office. These details establish the methods’ availability. It also quotes one source as recommending against the use of over-the-counter home screening tests for this disease. The story notes that what’s novel here is that the U.S. Preventive Task Force recently finalized their guidelines on colon cancer screening. There is no indication that this story relied on a news release. Claim: You Could Skip Your Colonoscopy If You’re Willing To Collect Your Poop

Answer: This story points out that, based on available data, two at-home screening tests appear to be equally effective compared to the more traditional, and more invasive, sigmoidoscopy and colonoscopy. We have only minor quibbles with the story–overall, it provided an excellent assessment of the at-home test options, particularly the fecal immunochemical test. However, for any story about screening methods, particularly blood tests, we think it’s important to include the risks of false-positive and false-negative results, which carry harm. The story didn’t go there. Given that the public has reservations about aspects of the invasive screening methods, information suggesting that they might be adequately replaced by non-invasive approaches is important to the public’s health. All too often, colonoscopy is promoted as the “gold standard” and no mention is made of effective alternatives. This news story does a good job explaining options, and also explores the reasons why so many Americans think that screening with colonoscopy is the best way to be screened for colon cancer and why that attitude is not supported by the evidence and may (in rare cases) be much worse than non-invasive screening methods.


Question: Paragraph: “This pandemic is not only a public health crisis, it is also fueling an economic crisis the likes of which we have not seen since the Great Depression,” Hancock said at a news conference. Denver has seen steep declines in sales, lodging and other taxes since the pandemic hit Colorado two months ago, and the state is still under a safer-at-home order that has placed restrictions on businesses. City leaders say the drop in tax revenue is affecting the fund that pays for police and fire services, as well as street maintenance. American cities, from Puyallup, Washington, to Miramar, Florida, have also furloughed employees to save money in the face of dire economic forecasts. In April, Los Angeles Mayor Eric Garcetti released a spending plan he called “a document of our pain” that includes service cuts and furloughs for nearly 16,000 workers. Under the proposal, city employees would take 26 furlough days, the equivalent of a 10% pay cut, in the coming year. The spending reductions in Los Angeles are likely to be a sign of what’s to come at city halls across the nation, as jobless lines grow and local treasuries see steep drops in tax revenue. Denver’s planned furloughs, which do not apply to uniformed employees like firefighters, police officers and sheriff’s deputies, will save the city about $16 million. The city also is reducing travel, hiring and purchases, and it is asking departments to cut 7.5% from their budgets. About 3,000 of Denver’s 12,000 employees are uniformed workers. “I want everyone to know that we have worked to exhaust every other tool we had before taking this step,” said Hancock, who repeated his call for lawmakers to include cities in the next federal stimulus package. “The reality is this: If cities can’t recover, there will be no national recovery,” he said. Brendan Hanlon, the city’s chief financial officer, said he thought the fallout from the 2008-2009 Great Recession was astonishing, but the current crisis will be harder to address. “I could have never imagined seeing the numbers that we’re seeing right now and the gravity that it means to the services that we provide to the public every day here in Denver,” he said. The city last instituted furloughs in 2011. A survey by the National League of Cities found nearly universal agreement that cities would be hit hard by revenue shortfalls caused by the coronavirus outbreak, and in many cases furloughs and layoffs would be used to close budget gaps. Claim: Denver to furlough thousands of workers amid coronavirus.

Answer:
Denver Mayor Michael Hancock said Thursday that thousands of city employees, including himself, will be furloughed for eight days this year to help close what is expected to be a $226 million budget gap caused by the coronavirus, joining mayors across the country that have made the same move or are thinking about it.